Skip to content

13F-HR filed by Sarissa Capital Management LP

Sarissa Capital Management LP filed this 13F-HR for the quarter ended 2019-03-31, filed 2019-05-15, with 11 holding rows worth $664,251,000.

Accession
0001567619-19-011163
Filed
2019-05-15
Accepted by EDGAR
acceptance time not in the bulk data set
Ingested
Source
SEC quarterly data set

Original filing

13F report for Q1 2019

A holdings report, 11 entries on the cover page, a total value of $664,251,000 stated on the cover page (in dollars after the unit check, H1), rows summing to $664,251,000 with VALUE read as thousands by filing date, 13F file number 028-15935. The quarter's positions are built on this report. The resolved quarter.

The information table after summing rows of one CUSIP and put or call (H4), with the CUSIP and issuer name as filed. Values in dollars after the unit check (method).

Issuer as filedCUSIPClassAmountValueValue read asType
ALLERGAN PLCG0177J108SHS868,000$127,083,000thousands by filing date
BIOGEN INC COM09062X103Stock524,658$124,018,000thousands by filing date
IRONWOOD PHARMACEUTICALS INC46333X108COMMON STOCK7,542,200$102,045,000thousands by filing date
MEDICINES CO584688105COM3,636,000$101,626,000thousands by filing date
INNOVIVA INC45781M101COM6,026,100$84,546,000thousands by filing date
PUMA BIOTECHNOLOGY INC74587V107COMMON STOCK1,417,000$54,965,000thousands by filing date
INTERCEPT PHARMACEUTICALS IN45845P108COM320,000$35,795,000thousands by filing date
Mersana Therapeutics Inc59045L106Common Stock3,750,000$19,725,000thousands by filing date
JAZZ PHARMACEUTICALS PLC SHS USDG50871105Stock100,000$14,295,000thousands by filing date
AbbVie,Inc.00287Y109COM1,000$80,000thousands by filing date
MIRATI THERAPEUTICS INC60468T105COM1,000$73,000thousands by filing date

Amendment chain

FilingRoleFiledAcceptedIngested
13F-HR 0001567619-19-011163this filing2019-05-15acceptance time not in the bulk data set